{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:31:10Z","timestamp":1789601470280,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paraneoplastic neurological syndromes constitute rare neurological complications of malignant disease, manifesting in &lt;1% of patients with cancer. Opsoclonus-myoclonus syndrome (OMS) presents with chaotic ocular saccades (opsoclonus), spontaneous muscular jerking (myoclonus) that may be accompanied by ataxia, strabismus, aphasia, or mutism. Its paraneoplastic variant in the adult is most commonly associated with small-cell lung cancer, followed by breast cancer. Importantly, neurological symptoms usually precede the diagnosis of breast cancer and tend to recure after its treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 43-year-old premenopausal Caucasian woman with a medical history of hypertension was admitted following an episode of focal seizure. This progressed to generalised tonic-clonic seizures and she was subsequently loaded with phenytoin, valproate, and levetiracetam. Initial workup included whole body CT scan, viral and autoimmune serology. The CT scan revealed an enhancing right axillary lymph node, which in combination with Anti-Ri antibody positivity raised the spectre of paraneoplastic OMS. MRI of the head revealed subtle nonspecific white matter signal change within the centrum semiovale without any mass lesions, while MRI of the spine was unremarkable. An uncomplicated right mastectomy and axillary lymph node clearance was performed: histopathology revealed a 9-mm, grade 2, oestrogen receptor-positive, progesterone receptor-negative (ER8, PR0), Her2-negative invasive ductal carcinoma, and 4\/6 positive lymph nodes (T1b N2 M0). Two months later, she was readmitted with vertigo, diplopia, facial weakness, and ataxia, setting the diagnosis anti-Ri syndrome recurrence. MDT recommended mammogram and ultrasound of the left breast, which were normal. Subsequently, four months after initial discharge, she suffered another neurological recurrence; due to concomitant abdominal pain, PET-CT was performed demonstrating a hypermetabolic right ovarian focus. Bilateral salpingo-oophorectomy was performed as per gynaecology MDT and final histology showed normal tubes and ovaries. She has remained on remission since then, with a negative annual mammogram follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, we report a case of OMS associated with breast cancer anti-Ri onconeural antibody. Its manifestations preceded the diagnosis of malignancy and it persisted after cancer treatment, underlining the importance for high clinical suspicion in cases of classical paraneoplastic neurological syndromes as well as the need for long-term clinical follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-021-02436-7","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T20:21:02Z","timestamp":1637007662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Breast cancer-associated opsoclonus-myoclonus syndrome: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Aikaterini","family":"Kostoglou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Vlastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Bakalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashis","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"2436_CR1","first-page":"311","volume-title":"Cancer and the nervous system","author":"RA Henson","year":"1982","unstructured":"Henson RA, Urich H. Part III. Paraneoplastic disorders. In: Henson RA, Urich H, eds. Cancer and the nervous system. Oxford: Blackwell Scientific Publications, 1982:311\u2013451."},{"key":"2436_CR2","series-title":"Contemporary Neurology Series","first-page":"96","volume-title":"Neurologic Complications of Cancer","author":"LR Rogers","year":"2009","unstructured":"Rogers LR. Neurologic Complications of Cancer, Contemporary Neurology Series, vol. 11. 2nd ed; 2009. p. 96\u20137. Neuro Oncol","edition":"2"},{"key":"2436_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","volume":"16","author":"F Graus","year":"2019","unstructured":"Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019;16:535\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"2436_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-016-0058-x","volume":"5","author":"I Fanous","year":"2016","unstructured":"Fanous I, Dillon P. Paraneoplastic neurological complications of breast cancer. Exp Hematol Oncol. 2016;5:29.","journal-title":"Exp Hematol Oncol"},{"key":"2436_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s001099900042","volume":"77","author":"RF Wang","year":"1999","unstructured":"Wang RF. Human tumor antigens: implications for cancer vaccine development. J Mol Med. 1999;77:640\u201355.","journal-title":"J Mol Med"},{"key":"2436_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10549-017-4566-0","volume":"167","author":"BL Murphy","year":"2018","unstructured":"Murphy BL, Zalewski NL, Degnim AC, McKeon A, Flanagan EP, Pittock SJ, et al. Breast cancer-related paraneoplastic neurologic disease. Breast Cancer Res Treat. 2018;167:771\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"2436_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/brain\/124.2.437","volume":"124","author":"L Bataller","year":"2001","unstructured":"Bataller L, Graus F, Saiz A, Vilchez JJ. Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124:437\u201343.","journal-title":"Brain"},{"key":"2436_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ana.410290303","volume":"29","author":"FA Luque","year":"1991","unstructured":"Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC Jr, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29:241\u201351.","journal-title":"Ann Neurol"},{"key":"2436_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0960-9776(03)00011-0","volume":"12","author":"G Gatti","year":"2003","unstructured":"Gatti G, Simsek S, Kurne A, Zurrida S, Naninato P, Veronesi P, et al. Paraneoplastic neurological disorders in breast cancer. Breast. 2003;12:203\u20137.","journal-title":"Breast."},{"key":"2436_CR10","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1073\/pnas.93.10.4529","volume":"93","author":"RB Darnell","year":"1996","unstructured":"Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A. 1996;93:4529\u201336.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2436_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMra023009","volume":"349","author":"RB Darnell","year":"2003","unstructured":"Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543\u201354.","journal-title":"N Engl J Med"},{"key":"2436_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13256-020-02410-z","volume":"14","author":"G Sena","year":"2020","unstructured":"Sena G, Gallo G, Vescio G, Gambardella D, de Franciscis S, Renne M. Anti-Ri-associated paraneoplastic ophthalmoplegia-ataxia syndrome in a woman with breast cancer: a case report and review of the literature. J Med Case Rep. 2020;14:67.","journal-title":"J Med Case Rep"},{"key":"2436_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","volume":"75","author":"F Graus","year":"2004","unstructured":"Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2436_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/bcr3620","volume":"16","author":"C Criscitiello","year":"2014","unstructured":"Criscitiello C, et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res. 2014;16:204.","journal-title":"Breast Cancer Res"},{"key":"2436_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1212\/WNL.18.11.1041","volume":"18","author":"C Ellenberger","year":"1968","unstructured":"Ellenberger C, CampaJF NMG. Opsoclonus and parenchymatous degeneration of the cerebellum. Neurology. 1968;18:1041\u20136.","journal-title":"Neurology"},{"key":"2436_CR16","first-page":"305","volume":"37","author":"W Royal","year":"1987","unstructured":"Royal W, Galasko DR, McKhann GM, Cunningham JM, Dropcho EJ. Clinical course, immunologic, and biochemical features of a patient with para-neoplastic cerebellar dysfunction. Neurology. 1987;37:305\u20136.","journal-title":"Neurology"},{"key":"2436_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/1043454204272560","volume":"22","author":"ED Tate","year":"2005","unstructured":"Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs. 2005;22:8\u201319.","journal-title":"J Pediatr Oncol Nurs"},{"key":"2436_CR18","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/archneurol.2012.1173","volume":"69","author":"JP Klaas","year":"2012","unstructured":"Klaas JP, Ahlskog JE, Pittock SJ, Matsumoto JY, Aksamit AJ, Bartleson JD, et al. Adult-onset opsoclonus\u2013myoclonus syndrome. Arch Neurol. 2012;69:1598\u2013607.","journal-title":"Arch Neurol"},{"key":"2436_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4065\/mcp.2010.0099","volume":"85","author":"LC Pelosof","year":"2010","unstructured":"Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85:838\u201354.","journal-title":"Mayo Clin Proc"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02436-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-021-02436-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02436-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T20:21:59Z","timestamp":1637007719000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-021-02436-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2436"],"URL":"https:\/\/doi.org\/10.1186\/s12957-021-02436-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-465161\/v1","asserted-by":"object"}]},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"25 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication was obtained by the patient for this case report presentation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work; no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"328"}}